Chinese Journal of Antituberculosis ›› 2019, Vol. 41 ›› Issue (12): 1269-1276.doi: 10.3969/j.issn.1000-6621.2019.12.007
• Original Articles • Previous Articles Next Articles
Min WANG,Jing LI,Yang-yi ZHANG,Li-li WANG,Chen-lei YU,Yuan JIANG,Qi-chao PAN
Online:
2019-12-10
Published:
2019-12-13
Contact:
Yuan JIANG,Qi-chao PAN
Min WANG,Jing LI,Yang-yi ZHANG,Li-li WANG,Chen-lei YU,Yuan JIANG,Qi-chao PAN. The status and risk factors of drug resistance tuberculosis in Shanghai, 2013—2017[J]. Chinese Journal of Antituberculosis, 2019, 41(12): 1269-1276. doi: 10.3969/j.issn.1000-6621.2019.12.007
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2019.12.007
一般资料 | 患者例数 | 构成比(%) | 一般资料 | 患者例数 | 构成比(%) |
---|---|---|---|---|---|
年龄组(岁) | 本市人口 | 3395 | 45.61 | ||
15~ | 1541 | 20.70 | 流动人口 | 4048 | 54.39 |
25~ | 1687 | 22.67 | 治疗史 | ||
35~ | 895 | 12.02 | 初治 | 6854 | 92.09 |
45~ | 963 | 12.94 | 复治 | 589 | 7.91 |
55~ | 1024 | 13.76 | 年份 | ||
65~104 | 1333 | 17.91 | 2013 | 1814 | 24.37 |
性别 | 2014 | 1622 | 21.79 | ||
男 | 5532 | 74.32 | 2015 | 1385 | 18.61 |
女 | 1911 | 25.68 | 2016 | 1374 | 18.46 |
户籍 | 2017 | 1248 | 16.77 |
年份 | 总株数 | 初治 株数 | 复治 株数 | 耐药 | 耐多药 | 多耐药 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
合计 | 初治 | 复治 | 合计 | 初治 | 复治 | 合计 | 初治 | 复治 | ||||
2013 | 1814 | 1670 | 144 | 402(22.16) | 341(20.42) | 61(42.36) | 107(5.90) | 76(4.55) | 31(21.53) | 77(4.24) | 64(3.83) | 13(9.03) |
2014 | 1622 | 1465 | 157 | 375(23.12) | 315(21.50) | 60(38.22) | 75(4.62) | 52(3.55) | 23(14.65) | 77(4.75) | 63(4.30) | 14(8.92) |
2015 | 1385 | 1273 | 112 | 297(21.44) | 262(20.58) | 35(31.25) | 77(5.56) | 60(4.71) | 17(15.18) | 53(3.83) | 47(3.69) | 6(5.36) |
2016 | 1374 | 1269 | 105 | 269(19.58) | 231(18.20) | 38(36.19) | 72(5.24) | 52(4.10) | 20(19.05) | 59(4.29) | 53(4.18) | 6(5.71) |
2017 | 1248 | 1177 | 71 | 222(17.79) | 201(17.08) | 21(29.58) | 40(3.21) | 33(2.80) | 7(9.86) | 44(3.53) | 42(3.57) | 2(2.82) |
合计 | 7443 | 6854 | 589 | 1565(21.03) | 1350(19.70) | 215(36.50) | 371(4.98) | 273(3.98) | 98(16.64) | 310(4.16) | 269(3.92) | 41(6.96) |
15.685 | 7.817 | 3.606 | 6.554 | 8.576 | 2.223 | 1.176 | 0.110 | 3.841 | ||||
P值 | 0.004 | 0.005 | 0.058 | 0.011 | 0.073 | 0.136 | 0.278 | 0.740 | 0.050 |
年份 | 总株数 | 初治 株数 | 复治 株数 | 对利福平耐药 | 对异烟肼耐药 | 对链霉素耐药 | 对乙胺丁醇耐药 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
耐药 | 初治 | 复治 | 耐药 | 初治 | 复治 | 耐药 | 初治 | 复治 | 耐药 | 初治 | 复治 | ||||
2013 | 1814 | 1670 | 144 | 126 (6.95) | 90 (5.39) | 36 (25.00) | 232 (12.79) | 182 (10.90) | 50 (34.72) | 298 (16.43) | 255 (15.27) | 43 (29.86) | 105 (5.79) | 79 (4.73) | 26 (18.06) |
2014 | 1622 | 1465 | 157 | 91 (5.61) | 64 (4.37) | 27 (17.20) | 189 (11.65) | 144 (9.83) | 45 (28.66) | 287 (17.69) | 246 (16.79) | 41 (26.11) | 79 (4.87) | 54 (3.69) | 25 (15.92) |
2015 | 1385 | 1273 | 112 | 99 (7.15) | 77 (6.05) | 22 (19.64) | 154 (11.12) | 131 (10.29) | 23 (20.54) | 219 (15.81) | 192 (15.08) | 27 (24.11) | 78 (5.63) | 63 (4.95) | 15 (13.39) |
2016 | 1374 | 1269 | 105 | 83 (6.04) | 61 (4.81) | 22 (20.95) | 157 (11.43) | 127 (10.01) | 30 (28.57) | 206 (14.99) | 176 (13.87) | 30 (28.57) | 53 (3.86) | 40 (3.15) | 13 (12.38) |
2017 | 1248 | 1177 | 71 | 48 (3.85) | 39 (3.31) | 9 (12.68) | 117 (9.38) | 105 (8.92) | 12 (16.90) | 162 (12.98) | 149 (12.66) | 13 (18.31) | 28 (2.24) | 23 (1.95) | 5 (7.04) |
合计 | 7443 | 6854 | 589 | 447 (6.01) | 331 (4.83) | 116 (19.69) | 849 (11.41) | 689 (10.05) | 160 (27.16) | 1172 (15.75) | 1018 (14.85) | 154 (26.15) | 343 (4.61) | 259 (3.78) | 84 (14.26) |
7.777 | 3.589 | 2.393 | 7.221 | 2.163 | 6.621 | 9.260 | 6.436 | 1.812 | 20.562 | 13.070 | 5.134 | ||||
P值 | 0.005 | 0.058 | 0.122 | 0.007 | 0.141 | 0.010 | 0.002 | 0.011 | 0.178 | 0.000 | 0.000 | 0.024 |
耐药类型 | 合计 | 初治 | 复治 | χ2值 | P值 | |||
---|---|---|---|---|---|---|---|---|
株数 | 耐药率(%) | 株数 | 耐药率(%) | 株数 | 耐药率(%) | |||
单耐药 | 884 | 11.88 | 808 | 11.79 | 76 | 12.90 | 0.644 | 0.422 |
R | 38 | 0.51 | 27 | 0.39 | 11 | 1.87 | - | 0.000 |
H | 218 | 2.93 | 190 | 2.77 | 28 | 4.75 | 7.492 | 0.006 |
S | 585 | 7.86 | 549 | 8.01 | 36 | 6.11 | 2.698 | 0.101 |
E | 43 | 0.58 | 42 | 0.61 | 1 | 0.17 | - | 0.256 |
耐2种药 | 316 | 4.25 | 273 | 3.98 | 43 | 7.30 | 14.683 | 0.000 |
R+H | 35 | 0.47 | 28 | 0.41 | 7 | 1.19 | - | 0.018 |
R+S | 22 | 0.31 | 6 | 0.23 | 6 | 1.02 | - | 0.006 |
R+E | 8 | 0.11 | 8 | 0.12 | 0 | 0.00 | - | 1.000 |
H+S | 226 | 3.04 | 199 | 2.90 | 27 | 4.58 | 5.203 | 0.023 |
H+E | 13 | 0.17 | 10 | 0.15 | 3 | 0.51 | - | 0.078 |
S+E | 12 | 0.16 | 12 | 0.18 | 0 | 0.00 | - | 0.616 |
耐3种药 | 165 | 2.22 | 133 | 1.94 | 32 | 5.43 | 30.519 | 0.000 |
R+H+S | 98 | 1.32 | 82 | 1.20 | 16 | 2.72 | 9.646 | 0.002 |
R+H+E | 38 | 0.51 | 27 | 0.39 | 11 | 1.87 | - | 0.000 |
R+S+E | 8 | 0.11 | 7 | 0.10 | 1 | 0.17 | - | 0.480 |
H+S+E | 21 | 0.28 | 17 | 0.25 | 4 | 0.68 | - | 0.079 |
耐4种药 | ||||||||
R+H+S+E | 200 | 2.69 | 136 | 1.98 | 64 | 10.87 | 163.623 | 0.000 |
耐药 | 1565 | 21.03 | 1350 | 19.70 | 215 | 36.50 | 92.256 | 0.000 |
耐多药 | 371 | 4.98 | 273 | 3.98 | 98 | 16.64 | 183.415 | 0.000 |
多耐药 | 310 | 4.16 | 269 | 3.92 | 41 | 6.96 | 12.527 | 0.000 |
任意耐R | 447 | 6.01 | 311 | 4.83 | 116 | 19.69 | 212.318 | 0.000 |
任意耐H | 849 | 11.41 | 689 | 10.05 | 160 | 27.16 | 157.167 | 0.000 |
任意耐S | 1172 | 15.75 | 1018 | 14.85 | 154 | 26.15 | 52.142 | 0.000 |
任意耐E | 343 | 4.61 | 259 | 3.78 | 84 | 14.26 | 135.580 | 0.000 |
变量 | 总例数 | 耐药结核病 | 耐多药结核病 | ||||||
---|---|---|---|---|---|---|---|---|---|
患者例数 | 率(%) | χ2值 | P值 | 患者例数 | 率(%) | χ2值 | P值 | ||
年龄组(岁) | 55.201 | <0.001 | 32.024 | <0.001 | |||||
15~ | 1541 | 309 | 20.05 | 61 | 3.96 | ||||
25~ | 1687 | 372 | 22.05 | 96 | 5.69 | ||||
35~ | 895 | 206 | 23.02 | 45 | 5.03 | ||||
45~ | 963 | 243 | 25.23 | 70 | 7.27 | ||||
55~ | 1024 | 244 | 23.83 | 62 | 6.05 | ||||
65~104 | 1333 | 191 | 14.33 | 37 | 2.78 | ||||
性别 | 0.034 | 0.855 | 0.045 | 0.832 | |||||
男 | 5532 | 1166 | 21.08 | 274 | 4.95 | ||||
女 | 1911 | 399 | 20.88 | 97 | 5.08 | ||||
户籍 | 1.855 | 0.173 | 0.163 | 0.687 | |||||
本市人口 | 3395 | 690 | 20.32 | 173 | 5.10 | ||||
流动人口 | 4048 | 875 | 21.62 | 198 | 4.89 | ||||
治疗史 | 92.256 | <0.001 | 183.415 | <0.001 | |||||
初治 | 6854 | 1350 | 19.70 | 273 | 3.98 | ||||
复治 | 589 | 215 | 36.50 | 98 | 16.64 | ||||
合计 | 7443 | 1565 | 21.03 | 371 | 4.98 |
参数 | 耐药结核病 | 耐多药结核病 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
β值 | s | Wald χ2值 | P值 | OR(95%CI)值 | β值 | s | Wald χ2值 | P值 | OR(95%CI)值 | |
常量 | -1.390 | 0.098 | 200.440 | <0.001 | -3.069 | 0.190 | 261.804 | <0.001 | ||
年龄组(岁) | ||||||||||
25~ | 0.087 | 0.087 | 0.994 | 0.319 | 1.091 (0.920~1.294) | 0.280 | 0.170 | 2.728 | 0.099 | 1.323 (0.949~1.844) |
35~ | 0.118 | 0.103 | 1.321 | 0.250 | 1.126 (0.920~1.377) | 0.070 | 0.205 | 0.115 | 0.735 | 1.072 (0.717~1.603) |
45~ | 0.193 | 0.102 | 3.559 | 0.059 | 1.212 (0.993~1.481) | 0.337 | 0.191 | 3.110 | 0.078 | 1.400 (0.963~2.035) |
55~ | 0.098 | 0.106 | 0.856 | 0.355 | 1.103 (0.896~1.359) | 0.068 | 0.204 | 0.110 | 0.741 | 1.070 (0.717~1.597) |
65~104 | -0.543 | 0.113 | 23.036 | <0.001 | 0.581 (0.466~0.725) | -0.797 | 0.235 | 11.538 | 0.001 | 0.451 (0.285~0.714) |
性别 | -0.002 | 0.067 | 0.001 | 0.979 | 0.998 (0.875~1.138) | -0.088 | 0.126 | 0.487 | 0.485 | 0.916 (0.716~1.172) |
户籍 | -0.019 | 0.068 | 0.079 | 0.779 | 0.981 (0.859~1.121) | -0.163 | 0.126 | 1.681 | 0.195 | 0.850 (0.664~1.087) |
治疗史 | 0.904 | 0.093 | 93.722 | <0.001 | 2.469 (2.056~2.964) | 1.636 | 0.132 | 153.545 | <0.001 | 5.135 (3.964~6.652) |
[1] | World Health Organization. Global tuberculosis report 2019. Genenva:World Health Organization, 2019. |
[2] |
李静, 张阳奕, 武洁 , 等. 2007—2012年上海市结核病耐药趋势分析. 中国防痨杂志, 2014,36(1):25-30.
doi: 10.3969/j.issn.1000-6621.2014.01.006 URL |
[3] | Zhu L, Yang YZ, Guan HY , et al. Trends in drug-resistant tuberculosis after the implementation of the DOTS strategy in Shenzhen, China, 2000—2013. Int J Tuberc Lung Dis, 2017,21(7):759-765. |
[4] | He XC, Tao NN, Liu Y , et al. Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China. BMC Infect Dis, 2017,17(1):555. |
[5] | Zhou M, Liu S, Li Q , et al. Drug resistance characteristics of Mycobacterium tuberculosis isolates between 2014 and 2017 in Sichuan, China: A retrospective study. PLoS One, 2018,13(12):e209902. |
[6] | 中华人民共和国国家卫生和计划生育委员会. WS 196—2017结核病分类. 2017-11-09. |
[7] | 赵雁林, 逄宇 . 结核病实验室检验规程. 北京: 人民卫生出版社, 2015: 59-65. |
[8] | 全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012,34(8):485-508. |
[9] | Mustazzolu A, Borroni E, Cirillo DM , et al. Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009-2016. Eur Respir J , 2018,52(1).pii: 1800070. |
[10] | 于梅, 车洋, 平国华 , 等. 2007年至2010年宁波市结核病耐药趋势及影响因素. 中华传染病杂志, 2012,30(1):48-52. |
[11] | 王宝英, 孙强, 张健 , 等. 秦皇岛市结核病患者一线抗结核药物的耐药性调查. 临床肺科杂志, 2019,24(8):1454-1458. |
[12] | 龚德华, 李艳红, 万燕萍 , 等. 2013—2016年湖南省耐多药结核病疫情特征. 中国感染控制杂志, 2017,16(8):708-713. |
[13] | Li Q, Zhao G, Wu L , et al. Prevalence and patterns of drug resistance among pulmonary tuberculosis patients in Hangzhou, China. Antimicrob Resist Infect Control, 2018,7:61. |
[14] | Zhao Y, Zhao B, Xu S , et al. National survey of drug-resis-tant tuberculosis in China. N Engl J Med, 2012,366(23):2161-2170. |
[15] | Yang C, Luo T, Shen X , et al. Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. Lancet Infect Dis, 2017,17(3):275-284. |
[16] | Nsofor CA, Jiang Q, Wu J , et al. Transmission is a Noticeable Cause of Resistance Among Treated Tuberculosis Patients in Shanghai, China. Scientific Reports, 2017,7(1):7691. |
[17] |
徐飚 . 强化耐多药患者诊治管理控制耐多药结核病流行. 中国防痨杂志, 2016,38(4):245-247.
doi: 10.3969/j.issn.1000-6621.2016.04.001 URL |
[18] | 陈诚, 李仁忠, 陈明亭 , 等. 全国结核病流行病学抽样调查及各省耐药监测中耐药结核病疫情. 疾病监测, 2013,28(4):265-268. |
[19] | Allix-Béguec C, Arandjelovic I, Bi L , et al. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. N Engl J Med, 2018,379(15):1403-1415. |
[20] | Gygli SM, Keller PM, Ballif M , et al. Whole-Genome Sequencing for Drug Resistance Profile Prediction in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2019,63(4).pii:e02175-18. |
[21] | Walker TM, Kohl TA, Omar SV , et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis, 2015,15(10):1193-1202. |
[22] | Jones JM, Armstrong LR . Delayed and Unreported Drug-Susceptibility Testing Results in the US National Tuberculosis Surveillance System,1993-2014. Public Health Rep, 2017,132(4):480-487. |
[23] | 白大鹏, 孔伟利, 张丽霞 . 2006—2017年天津市结核分枝杆菌耐药性分析. 中华医院感染学杂志, 2019,29(3):346-350. |
[1] | SU Qian, XIA Yong, LU Jia, WANG Dan-xia, HE Jin-ge. Analysis on the epidemiological characteristics of pulmonary tuberculosis among children aged 0-14 in Sichuan Province from 2009 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 942-947. |
[2] | SUN Hai-yan, LI Shuo, WANG Zhong-dong, REN Zhi-sheng, SONG Song, XUE Bai, ZHANG Hua-qiang, DAI Xiao-qi. Characteristics of the tuberculosis epidemic in schools in Qingdao in 2010—2019 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 994-997. |
[3] | Chinese Antituberculosis Association, Schools and Children Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus of clinical application of the recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 761-768. |
[4] | YANG Lei, WEI Fen, ZHANG Kai, QIU Jing-jing, WANG Ying-ying, DU Wei-xin, LU Jin-biao, TAO Li-feng, PU Jiang. Stability and efficacy study of recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 799-806. |
[5] | ZHANG Kai, TAO Li-feng, WEI Fen, DU Wei-xin, QIU Jing-jing, CHEN Wei, CHEN Bao-wen, ZHU Yin-meng, CHENG Xing, SU Cheng, ZHONG Zai-xin, LU Jin-biao, PU Jiang. Immune characteristics and preclinical animal safety studies of recombinant Mycobacterium tuberculosis fusion protein(EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 807-813. |
[6] | ZHANG Kai, SHEN Xiao-bing, TAO Li-feng, WEI Fen, CHEN Bao-wen, QIU Jing-jing, CHEN Wei, LU Jin-biao, ZHU Yin-meng, CHENG Xing, ZHONG Zai-xin, ZHAO Ai-Hua, PU Jiang. Establishment of quality standards for recombinant Mycobacterium tuberculosis fusion protein [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 814-820. |
[7] | DU Wei-xin, WEI Fen, LU Jin-biao, ZHAO Ai-hua, PU Jiang, WANG Guo-zhi, XU Miao. Preliminary establishment of national reference of the freeze-dried recombinant Mycobacterium tuberculosis allergen for the bulk potency evaluation [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 826-831. |
[8] | QU Meng-jin, LIANG Zheng-min, WANG Yuan-zhi, ZHOU Xiang-mei. Research progress of carbohydrate metabolism of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 874-879. |
[9] | SUN Qing, HUANG Hai-rong, WANG Gui-rong. In vitro activities and drug resistance mechanisms of bedaquiline, clofazimine and delamanid against common pathogenic non-tuberculous mycobacteria [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 880-884. |
[10] | SONG Yi-meng, LI Yuan-chun, HE Wen-cong, HE Ping, BAO Jing-jing, LIU Chun-fa, LIU Dong-xin, WANG Xin-yang, ZHAO Yan-lin, LI Yan-ming. Cost analysis of fluorescence PCR probe melting curve technique for the detection of Mycobacterium tuberculosis resistance in China [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 712-717. |
[11] | BAO Xun-di, JIANG Yue, LIANG Suo, CHENG Hong-yan, XIA Guang-xiu, WANG Chao, YE Qian, WANG Shu, WANG Qing. Analysis of the clinical isolation rate, population distribution and drug resistance of non-tuberculous mycobacteria in Anhui [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 718-724. |
[12] | ZHANG Jie, REN Yi-xuan, PAN Li-ping, ZHANG Zong-de. Application of whole genome sequencing in research of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 737-740. |
[13] | LAI Keng, LEI Yu, DU Yu-hua, WU Gui-feng, XIE Wei, SHEN Hong-cheng, ZHONG Zhi-qing, LI Tie-gang. Spatial-temporal analysis on tuberculosis among students in Guangzhou City during 2014-2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 590-596. |
[14] | MA Jin-bao, REN Fei, ZENG Ling-cheng, CHEN Ming-wei. Analysis of drug susceptibility of 680 patients with multidrug-resistant tuberculosis in Xi’an City from 2015 to 2019 [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 609-613. |
[15] | QIN Zhong-hua, JING Ye, DU Yan-qing, SONG Xiao-mei, ZHANG Li-xia. Spectrum and drug resistance analysis of 339 strains of nontuberculous mycobacterium isolated from clinical practice [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 630-633. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||